High sensitivity troponin outperforms contemporary assays in predicting major adverse cardiac events up to two years in patients with chest pain

Abstract

hsTnT outperformed contemporary TnI and TnT assays for the prediction of MACE at two years. Those with levels below the LOD for hsTnT identified a group of patients at very low risk for adverse events.